




FIG. 1




FIG. 2




FIG. 3




FIG. 4




FIG. 5




FIG. 6A




FIG. 6B




FIG. 6C




FIG. 6D




FIG. 6E




FIG. 6F

Lymphoma Diagnosis	No. of CLN-078 administrations	CRS	Serious AEs	Lymphopenia	Best clinical response ^a
Mantle Cell	7	None	Influenza A (grade 1)	Grade 3	Complete Response
Diffuse Large B cell	9	Grade 1	None	Grade 4 ^a	Partial Response
Follicular	24	Grade 1	None	Grade 4 ^a	Stable disease

^aLymphocyte counts in patients with grade 4 lymphopenia returned to baseline by day 7.
TEAEs, treatment-emergent adverse events; CR, complete response; CRS, cytokine release syndrome; FDG-PET, fludeoxyglucose-18 positron emission tomography; SC, subcutaneous

FIG. 7





FIG. 8



Note: The TCE is administered SC and absorbed into the central compartment, where it can distribute to the peripheral compartment, be eliminated, or bind to and crosslink to CD3 or CD19 on T cells and B cells, respectively. CD3 and CD19 are synthesized and internalized in each compartment. B cells proliferate and die in each compartment and the formation of trimers can affect these processes as described in the text.

FIG. 9




FIG. 10B




FIG. 10A




FIG. 11B

FIG. 11A




FIG. 12




FIG. 13




FIG. 14

Selectivity (Runs 5, 8 and 9)																
Run ID	Matrix Type	Lot ID	Unspiked* samples	0.0625 ng/mL (LOQ)						Spiked samples 6.4000 ng/mL (ROC)						
				Measured Conc.	%CV	Mean %CV	%RE	%Rec.	Mean %RE	Measured Conc.	%CV	Mean %CV	%RE	%Rec.	Mean %RE	
5	Selectivity		1	BLQ	0.0629	18.8		0.6	100.6		5.9266	0.9		-7.8	97.2	
			2	BLQ	0.0574	2.2	-8.2	91.8		6.0149	1.0		-6.0	94.0		
			3	BLQ	0.0634	4.9	1.4	101.4		6.0189	0.7		3.4	103.4		
			4	BLQ	0.0625	2.3	0.0	100.0		6.0596	0.4		3.1	103.1		
			5	BLQ	0.0629	10.3	0.6	100.6		5.9800	3.0		-8.1	91.9		
			6	BLQ	0.0531	3.5	14017.0	14117.0	NA	5.6889	0.5	NA	-11.1	88.9	NA	
			7	BLQ	0.0635	3.6	5.3	105.3		5.8134	2.0		-15.5	84.7		
			8	BLQ	0.0629	5.5	0.6	100.6		5.9595	6.3		-14.2	85.8		
			9	BLQ	0.0646	5.7	3.4	103.4		5.9420	2.1		-6.5	93.5		
			10	BLQ	0.0503	3.6	13780.6	13840.5		5.9804	0.5		6.4	93.6		
8	Selectivity (SLE)		1	BLQ	0.0539	3.6	-5.8	94.2		7.4661	1.3		16.7	116.7		
			2	BLQ	0.0592	6.8	-5.3	94.7		6.9598	15.1		9.7	105.7		
			3	BLQ	0.0526	5.5	-15.8	84.2		6.7001	2.9		4.7	104.7		
			4	BLQ	0.0604	8.6	-3.4	96.6		6.4044	5.0		0.1	100.1		
			5	BLQ	0.0562	0.6	-10.1	89.9		6.3415	3.8		0.6	100.6		
			6	BLQ	0.0485	18.3	-20.3	79.7	NA	6.6468	6.7	NA	3.9	103.9	NA	
			7	BLQ	0.0380	17.5	-39.2	60.8		5.8160	5.2		-12.3	87.3		
			8	BLQ	0.0470	24.7	-24.8	75.2		6.9096	0.4		1.7	101.7		
			9	BLQ	0.0475	0.7	-24.0	76.0		6.5317	9.6		2.1	102.1		
			10	BLQ	0.0528	5.9	-15.5	84.5		6.9072	0.7		-1.5	98.5		
9	2% Homalysed 300 mg/dL Hydrogenox	E8A787867	BLQ	0.0591	3.8		-5.4	94.6		6.6535	2.4		3.7	103.7		
				0.0687	5.7	4.9	9.9	109.9	102.2	6.0548	4.6	3.4	7.2	107.2	113.7	
				0.0639	5.1		2.2	102.2		6.9886	3.0		24.8	129.8		
				0.0689	7		-3.5	96.5		5.4643	1.7		-14.6	85.4		
			BLQ	0.0534	1.4	4.7	21.5	121.5	106.3	7.1820	0.6	1.2	12.3	112.3	101.3	
				0.0680	4.6		1.0	101.0		7.1729	1.5		12.1	112.1		
*BLQ < 11.00 (0.0625 ng/mL)																
Bold denotes sample did not meet acceptance criteria.																

FIG. 15




FIG. 16




FIG. 17B




FIG. 17A




FIG. 18




FIG. 19A




FIG. 19B




FIG. 20B




FIG. 20A